Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Professor of Oncology, Department of Medicine
Roswell Park Cancer Institute
Associate Professor of Medicine
School of Medicine and Biomedical Sciences, State University of New York at Buffalo
Profile
Areas of Expertise: 
Bladder Cancer
Breast Cancer
Prostate Cancer
Testicular Cancer
Research
Research Interests: 
Novel therapies for breast and urothelial cancer
Background Information
Education and Training: 
MD - University of Pittsburgh, Pittsburgh, PA
Residency: 
University of Minnesota, Minneapolis, MN
Board Certification: 
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
University of Minnesota, Minneapolis, MN
Publications
Publications: 
  • Garber JE, Shahab N, Levine E, Winer E, Scalzo A, Orcutt J, Kimmick G, Paskett EM, Dressler L, Shapiro CL, Edge S, Atkins JN, Archer L, Kaplan E, Tolaney SM, Halabi S, Berliner N. Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. Journal of the National Cancer Institute 2010; 102(13):942-949
  • Albain KS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Lichter AS, Pritchard KI, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Osborne CK. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374(9707):2055-2063
  • Motzer RJ, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Kuzel TM, Kessinger A, Jonasch E, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7(6):618-630
  • Motzer RJ, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Kuzel TM, Kessinger A, Jonasch E, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7(6):672-693
  • Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A, Levine E. Length of survival in hospice for cancer patients referred from a comprehensive cancer center. American journal of hospice and palliative care 2009; 26(4):281-287
  • Ademuyiwa FO, Miller A, O'Connor T, Edge SB, Thorat MA, Sledge GW, Levine E, Badve S. The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast cancer research and treatment 2011; 126(3):797-802
  • Chadha MK, Ashraf U, Lawrence D, Tian L, Levine E, Silliman C, Escott P, Payne V, Trump DL. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. Prostate 2008; 68(13):1461-1466
  • O'connor T, Rustum Y, Levine E, Creaven P. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer. Cancer chemotherapy and pharmacology 2008; 61(1):125-131
  • Chen H, Mortazavi A, Levine E, Kamisetti S, Kamisetti S, Ramnath N. What did you think of the hematology/oncology rotation? A survey of internal medicine residents. Journal of cancer education 2007; 22(1):50-55
  • Society of Surgical Oncology Annual Meeting, Riley L, Quinones M, Piso P, Pitroff A, Pingpank J, Philippe G, Petrelli N, Onate-Ocana L, Morris D, Moran B, Misih RA, Martin R, Mann G, Mahteme H, Loggie B, Li B, Lange J, Rutstein L, Saha S, Sebbag G, Zoetmulder F, Zeh H, Younan R, Wilkinson N, Villar J, Verwaal V, Tuttle T, Torres-Melero J, Stewart J, Stojadinovic A, Spellman J, Shibata D, Shen P, Schneebaum S, Sardi A, Alrawi S, Lamont J, Kuhn J, Deraco M, de Bree E, Daniel S, Chu Q, Chu F, Chang CK, Bretcha-Boix P, Bieligk S, Barrios P, Barone R, Bartlett D, Baratti D, Alexander R, Yan TD, Levine E, Sugarbaker P, Sticca R, Dominguez-Parra L, Elias D, Kelley S, Kecmanovic D, Kane J, Hoefer R, Harrison L, Hartmann J, Hanna N, Gushchin V, Goodman M, Gonzalez-Moreno S, Gonzalez-Bayon L, Gomez-Portilla A, Glehen O, Gilly FN, Garofalo A, Foster J, Flynn R, Esquivel J. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Annals of surgical oncology 2007; 14(1):128-133
  • Lewis LD, Ratain MJ, Millard F, Otterson GA, Levine EG, Hollis DR, Bies RR, Egorin MJ, Relling MV, Valdivieso M, Dowell JE, Rosner GL, Miller AA, Cancer and Leukemia Group B. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clinical cancer research 2007; 13(11):3302-3311
  • Younis T, Milch R, Abul-Khoudoud N, Lawrence D, Mirand A, Levine EG. Length of survival of patients with cancer in hospice: a retrospective analysis of patients treated at a major cancer center versus other practice settings. Journal of palliative medicine 2007; 10(2):381-389
  • Ngamphaiboon N, Advani PP, O'Connor TL, Ademuyiwa FO, Levine EG, Riebandt G, Kossoff EB. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in patients with breast cancer: A retrospective analysis : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):1134
  • O'Connor T, Houde C, Dolce J, Bundy B, Nesline M, Davis W, Ambrosone C, Levine E, Edge SB, Coignet LJ. The presence of the FRA12E/SMRT fragile site in the genome of breast cancer (BC) patients is a predictor of metastatic development. Breast cancer research and treatment 2007; 106(Suppl. 1):S170-S171
  • Grivas P, Agarwal N, Siefker-Radtke AO, Daignault S, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Smith DC, Hussain M. Randomized phase II trial of gemcitabine/cisplatin (GC) with or without cetuximab (CET) in patients (pts) with advanced urothelial carcinoma (UC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4506
  • Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R. A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy : 2012 Genitourinary Cancers Symposium. Journal of clinical oncology 2012; 30(5 Suppl.):Abstract #318
  • Ademuyiwa FO, Bshara W, Attwood K, Morrison C, 4533, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PloS one 2012; 7(6):e38783
  • Ngamphaiboon N, O'Connor TL, Advani PP, Levine EG, Kossoff EB. Febrile neutropenia in adjuvant docetaxel and cyclophosphamide (TC) with prophylactic pegfilgrastim in breast cancer patients: a retrospective analysis. Medical oncology (Northwood, London, England) 2012; 29(3):1495-1501
  • O'Connor TL, Edge SB, Kossoff EB, Groman A, Wilding GE, Ademuyiwa FO, Levine EG, Watroba N, Ngamphaiboon N. Factors affecting the delivery of adjuvant/neoadjuvant chemotherapy in older women with breast cancer. Journal of geriatric oncology 2012; 3(4):320-328
Referral
Email: 
Ellis.Levine@RoswellPark.org
Fax: 
716-845-8008
Source URL (retrieved on 05/21/2013 - 4:05pm): http://www.roswellpark.org/ellis-levine